Marcain (Bupivacaine Hydrochloride)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilizing them in an inactive state. This prevents sodium influx, halting depolarization and stopping the transmission of pain signals, resulting in a reversible loss of sensation in the targeted region.

The appropriate dose of Marcain is determined by the prescribing clinician based on the type of procedure, patient weight, age, and overall health. Dosing guidelines are individualized, and the prescriber sets the exact amount and administration schedule.

Safety data for bupivacaine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To order Marcain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

The most common alternative to bupivacaine is lidocaine, which has a shorter duration of action and a faster onset. Bupivacaine provides longer-lasting anesthesia, making it preferred for procedures requiring extended pain control, but it also carries a higher risk of cardiotoxicity at elevated plasma levels.

Marcain should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture, and keep it out of reach of children. Do not freeze or shake the vial before use.

Marcain is administered by a qualified healthcare professional via epidural injection, peripheral nerve block, or direct infiltration into the target tissue. The solution is injected using sterile technique, and the dose is titrated to achieve the desired level of anesthesia while monitoring the patient closely.

Serious risks include cardiac arrhythmias, seizures, respiratory depression, prolonged motor block, severe allergic reactions, and systemic toxicity from high plasma concentrations. Prompt recognition of symptoms such as chest pain, convulsions, or difficulty breathing is essential for immediate intervention.

Marcain should not be used in patients with known hypersensitivity to bupivacaine or other amide‑type local anesthetics, in individuals with severe cardiac conduction disorders, or in those with uncontrolled epilepsy. Caution is also advised for patients with significant liver disease or those receiving other agents that lower seizure threshold.